Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

2 months ago

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use…

Glucose Health, Inc. Appoints Veteran Financial Executive Edmund “Ned” Burke to Its Board of Directors

2 months ago

BENTONVILLE, Ark., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) is pleased to announce the appointment of…

Glucose Health, Inc. Appoints Veteran Financial Executive Edmund “Ned” Burke to Its Board of Directors

2 months ago

BENTONVILLE, Ark., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) is pleased to announce the appointment of…

Glucose Health, Inc. Appoints Veteran Financial Executive Edmund “Ned” Burke to Its Board of Directors

2 months ago

BENTONVILLE, Ark., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) is pleased to announce the appointment of…

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

2 months ago

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

2 months ago

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

2 months ago

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

2 months ago

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

2 months ago

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

2 months ago

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

Show more Posts
Show previous Posts